In 2023, 17.2 million packages of insulin were sold in Russia, which is 7.5% more than in 2022. The market volume reached 35.5 billion rubles (at distributor prices, including VAT), marking a 17% increase from the previous year.
The majority of the Russian insulin market – 89% – is occupied by Sanofi, Novo Nordisk and Geropharm. The share of Russian companies is 24.6% in monetary terms and 38.8% in physical terms. According to Nikolai Bespalov, development director of the analytical company RNC Pharma, most of the insulin drugs are localized in Russia, and if you take them into account, the share will be about 95% in money and 88% in packages.
